Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care
Tempus AI, Inc. - Class A (TEM)
Company Research
Source: Business Wire
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer,” in JAMA Network Open.Tempus recently conducted a retrospective study of more than 5,500 patients with advanced non-small cell lung cancer (NSCLC) and found that concurrent RNA- and DNA-based next-generation sequencing (NGS) led to the detection of more actionable structural variants compared to DNA sequencing alone. Specifically, 8.8% of patients had at least one actionable variant – ALK, RET, ROS1, or NTRK1/2/3 fusions, or MET exon 14 skipping alterations – identified by one or both assays. Overall, the concurrent use of RNA and DNA sequencing resulted in a 15.3% increase in identifying patients with actionable variants and more than doubled the detection of emerging, ra
Show less
Read more
Impact Snapshot
Event Time:
TEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEM alerts
High impacting Tempus AI, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
TEM
News
- Tempus AI, Inc. (NASDAQ: TEM) had its "neutral" rating re-affirmed by analysts at Piper Sandler. They now have a $70.00 price target on the stock, up previously from $40.00.MarketBeat
- Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR®Business Wire
- Tempus AI, Inc. (NASDAQ: TEM) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $65.00 price target on the stock, up previously from $45.00.MarketBeat
- Tempus AI, Inc. (TEM) Q3 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual MeetingBusiness Wire
TEM
Earnings
- 11/4/24 - Miss
TEM
Sec Filings
- 11/12/24 - Form SC
- 11/12/24 - Form SC
- 11/5/24 - Form 4
- TEM's page on the SEC website